Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
- 15 November 2001
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 108 (10), 1429-1437
- https://doi.org/10.1172/jci200113350
Abstract
Cardiac hypertrophy is a major cause of morbidity and mortality worldwide. The hypertrophic process is mediated, in part, by small G proteins of the Rho family. We hypothesized that statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, inhibit cardiac hypertrophy by blocking Rho isoprenylation. We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. These effects were associated with decreases in cell size, membrane Rho activity, superoxide anion (O2·̄) production, and intracellular oxidation, and were reversed with L-mevalonate or geranylgeranylpyrophosphate, but not with farnesylpyrophosphate or cholesterol. Treatments with the Rho inhibitor C3 exotoxin and with cell-permeable superoxide dismutase also decreased AngII-induced O2·̄ production and myocyte hypertrophy. Overexpression of the dominant-negative Rho mutant N17Rac1 completely inhibited AngII-induced intracellular oxidation and ANF promoter activity, while N19RhoA partially inhibited it, and N17Cdc42 had no effect. Indeed, Sim inhibited cardiac hypertrophy and decreased myocardial Rac1 activity and O2·̄ production in rats treated with AngII infusion or subjected to transaortic constriction. These findings suggest that statins prevent the development of cardiac hypertrophy through an antioxidant mechanism involving inhibition of Rac1.Keywords
This publication has 39 references indexed in Scilit:
- RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overloadJCI Insight, 1999
- Gq Signaling in Cardiac Adaptation and MaladaptationTrends in Cardiovascular Medicine, 1999
- Bacterial toxins that target Rho proteins.JCI Insight, 1997
- Angiotensin II Induces Cardiac Phenotypic Modulation and Remodeling In Vivo in RatsHypertension, 1995
- Signaling Pathways for Cardiac Growth and HypertrophyAnnals of the New York Academy of Sciences, 1995
- The small GTP-binding protein rac regulates growth factor-induced membrane rufflingCell, 1992
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Cardiac Hypertrophy in HypertensionNew England Journal of Medicine, 1987
- Long-term culture of contractile mammalian heart cells in a defined serum-free medium that limits non-muscle cell proliferation*Journal of Molecular and Cellular Cardiology, 1984